Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK.
European journal of pharmacology 1993 Sep 28This study, carried out in human cerebral cortical membranes, confirms previous findings in human substantia nigra that serotonin-5-O-carboxymethyl-glycyl[125I]tyrosinamide ([125I]GTI) labels a homogeneous population of recognition sites consistent with a 5-HT1D receptor pharmacology. In addition the results indicate that, under the assay conditions described, [125I]GTI specifically labels the 5-HT1D beta recognition site since ketanserin and ritanserin display a low affinity consistent with their activities at this subtype of the 5-HT1D receptor.
M S Beer, D N Middlemiss. Serotonin-5-O-carboxymethyl-glycyl[125I]tyrosinamide labels the 5-HT1D beta receptor subtype in human cortex. European journal of pharmacology. 1993 Sep 28;242(2):195-8
PMID: 8253115
View Full Text